The significance of defining preclinical or prodromal Parkinson's disease

被引:44
|
作者
Olanow, C. Warren [1 ,2 ]
Obeso, Jose A. [3 ]
机构
[1] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA
[3] Univ Navarra, Dept Neurol, E-31080 Pamplona, Spain
关键词
prodromal Parkinson's disease; Parkinson's disease; non-motor features; DELAYED-START TRIAL; DOUBLE-BLIND; RASAGILINE; DIAGNOSIS; THERAPIES; PATHOLOGY; FEATURES; NEED;
D O I
10.1002/mds.25019
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD. (C) 2012 Movement Disorder Society
引用
收藏
页码:666 / 669
页数:4
相关论文
共 50 条
  • [31] In vivo modeling of prodromal stage of Parkinson's disease
    Cerri, Silvia
    Blandini, Fabio
    JOURNAL OF NEUROSCIENCE METHODS, 2020, 342
  • [32] Symptoms and duration of the prodromal phase in Parkinson's disease
    Gonera, EG
    vantHof, M
    Berger, HJC
    vanWeel, C
    Horstink, WIM
    MOVEMENT DISORDERS, 1997, 12 (06) : 871 - 876
  • [33] Diet to beat the odds of prodromal Parkinson's disease?
    Tangney, Christy C.
    MOVEMENT DISORDERS, 2019, 34 (01) : 2 - 3
  • [34] MDS research criteria for prodromal Parkinson's disease
    Berg, Daniela
    Postuma, Ronald B.
    Adler, Charles H.
    Bloem, Bastiaan R.
    Chan, Piu
    Dubois, Bruno
    Gasser, Thomas
    Goetz, Christopher G.
    Halliday, Glenda
    Joseph, Lawrence
    Lang, Anthony E.
    Liepelt-Scarfone, Inga
    Litvan, Irene
    Marek, Kenneth
    Obeso, Jose
    Oertel, Wolfgang
    Olanow, C. Warren
    Poewe, Werner
    Stern, Matthew
    Deuschl, Guenther
    MOVEMENT DISORDERS, 2015, 30 (12) : 1600 - 1609
  • [35] Essential tremor as a prodromal feature of Parkinson's disease
    Yilmaz, Abdullah Yasir
    Jankovic, Joseph
    PARKINSONISM & RELATED DISORDERS, 2024, 128
  • [36] Heterogeneity in progression of prodromal features in Parkinson's disease
    Schrag, A.
    Zhelev, S. S.
    Hotham, S.
    Merritt, R. D.
    Khan, K.
    Graham, L.
    PARKINSONISM & RELATED DISORDERS, 2019, 64 : 275 - 279
  • [37] Plasma Glutathione and Prodromal Parkinson's Disease Probability
    Charisis, Sokratis
    Ntanasi, Eva
    Stamelou, Maria
    Xiromerisiou, Georgia
    Maraki, Maria
    Veskoukis, Aristidis S.
    Yannakoulia, Mary
    Kosmidis, Mary H.
    Anastasiou, Costas A.
    Giagkou, Nikolaos
    Dardiotis, Efthimios
    Hadjigeorgiou, Georgios
    Sakka, Paraskevi
    Kouretas, Demetrios
    Stefanis, Leonidas
    Scarmeas, Nikolaos
    MOVEMENT DISORDERS, 2022, 37 (01) : 200 - 205
  • [38] Experimental Animal Models of Prodromal Parkinson's Disease
    Yamakado, Hodaka
    Takahashi, Ryosuke
    JOURNAL OF PARKINSONS DISEASE, 2024, 14 : S369 - S379
  • [39] Ultrasonography Markers in Prodromal Parkinson's disease (PD)
    Secades Garcia, S.
    Perez, J.
    La Casa, B.
    Contreras, A.
    Grandas, F.
    MOVEMENT DISORDERS, 2024, 39 : S484 - S484
  • [40] Motor signs in the prodromal phase of Parkinson's disease
    Maetzler, Walter
    Hausdorff, Jeffrey M.
    MOVEMENT DISORDERS, 2012, 27 (05) : 627 - 633